ARS Pharmaceuticals (SPRY) EBT Margin: 2022-2025
Historic EBT Margin for ARS Pharmaceuticals (SPRY) over the last 3 years, with Sep 2025 value amounting to -163.66%.
- ARS Pharmaceuticals' EBT Margin rose 88798.00% to -163.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -63.59%, marking a year-over-year increase of 226536.00%. This contributed to the annual value of 9.29% for FY2024, which is 18122596.00% up from last year.
- ARS Pharmaceuticals' EBT Margin amounted to -163.66% in Q3 2025, which was up 45.98% from -302.95% recorded in Q2 2025.
- Over the past 5 years, ARS Pharmaceuticals' EBT Margin peaked at 54.51% during Q4 2024, and registered a low of -206,030.00% during Q2 2023.
- In the last 3 years, ARS Pharmaceuticals' EBT Margin had a median value of -758.97% in 2025 and averaged -38,074.13%.
- Its EBT Margin has fluctuated over the past 5 years, first tumbled by 20,466,276bps in 2023, then soared by 20,296,200bps in 2024.
- Quarterly analysis of 4 years shows ARS Pharmaceuticals' EBT Margin stood at -3,507.94% in 2022, then crashed by 20,466,276bps to -206,030.00% in 2023, then spiked by 20,296,200bps to 54.51% in 2024, then spiked by 88,798bps to -163.66% in 2025.
- Its EBT Margin stands at -163.66% for Q3 2025, versus -302.95% for Q2 2025 and -466.29% for Q1 2025.